all report title image
  • Published On : Mar 2022
  • Code : CMI4953
  • Industry : Pharmaceutical
  • Pages : 198
  • Formats :
Ingographics Image

Naloxone is an opioid overdose reversal drug that has been licenced by the U.S. Food and Drug Administration (FDA). It is an opioid antagonist, which means it attaches to opioid receptors and can counteract and prevent the effects of opioids such as heroin, morphine, and oxycodone. Intranasal spray (into the nose), intramuscular (into the muscle), subcutaneous (under the skin), and intravenous injection are all options for administering the medicine. Naloxone is widely available over the counter at pharmacies in the U.S. as it is not prescribed medicine. Naloxone can also be obtained for free from community-based distribution initiatives, local public health groups, or local health departments.

Market Dynamics

Key players in the market are focused on adopting strategies such as partnerships, acquisitions, and programs to expand their product portfolio which is expected to drive the market growth. For instance, on October 22, 2021, Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, announced the donation of 50,000 vials of Naloxone HCl Injection, USP – a treatment for reversing opioid overdoses to members of the Opioid Safety and Naloxone Network (OSNN) Buyers Club to help ease an acute shortage of the medicine currently facing non-profit harm-reduction programs which includes treatments for HIV, hepatitis C virus (HCV), HBV counseling and testing, and naloxone for overdose in the U.S. the Opioid Safety and Naloxone Network (OSNN) is a network of over 100 harm-reduction programs in the U.S that distribute naloxone to drug users and their families. Some of its member programs have been participating in community naloxone distribution for over 20 years. Hikma's donation will come from its state-of-the-art sterile injectable manufacturing facility in Cherry Hill, New Jersey, and will be made in collaboration with Hikma Community Health, a new division of Hikma dedicated to providing a variety of treatment options for substance use disorder and opioid overdose in the U.S.

Key features of the study:

  • This report provides an in-depth analysis of the U.S. Naloxone market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the U.S. Naloxone market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc.,  Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The U.S. Naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the U.S. Naloxone market

Detailed Segmentation:

  • U.S. Naloxone Market, By Drug Type:
    • Branded
    • Generic
  • U.S. Naloxone Market, By Route of Administration:
    • Intranasal Administration
    • Intramuscular Administration
    • Intravenous Administration
    • Others
  • U.S. Naloxone Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies  
  • Company Profiles
    • Mylan N.V. *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis AG
    • Indivior Plc.
    • ADAPT Pharma, Inc.
    • Amphastar Pharmaceuticals, Inc.
    • INSYS Therapeutics, Inc.
    • Mundipharma International Limited
    • Kaleo, Inc.
    • Kern Pharma, S.L
    • Samarth Life Sciences Pvt. Ltd.
    • Opiant Pharmaceuticals
    • Pfizer
    • Sandoz
    • Amneal Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

  • U.S. Naloxone Market, By Drug Type:
    • Branded
    • Generic
  • U.S. Naloxone Market, By Route of Administration:
    • Intranasal Administration
    • Intramuscular Administration
    • Intravenous Administration
    • Others
  • U.S. Naloxone Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies  

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo